🔗 Share this article The Global Health Body Issues Warning Over Severe Scarcity of Obesity Injections Under one in 10 patients that would benefit from weight-loss injections such as Wegovy are able to get them, caution the WHO as it issues its initial recommendations on the medications. Given over a billion individuals worldwide currently classified as obese, it is advocating for more widespread and fairer availability to these injectable treatments. Per projections, over two billion are projected to be living with obesity by 2030 unless action is taken. "Our new guidelines affirms that obesity is a chronic disease that can be addressed with holistic and lifelong support," stated its chief Tedros Adhanom Ghebreyesus. Substantial prices, insufficient output, and distribution challenges are key hurdles to widespread access to the treatments that can aid individuals in losing significant weight, explains the body. GLP-1 Therapy Shortage Despite the present best projected scenario, the manufacturing of GLP-1 therapies would only suffice for around 100 million people – fewer than 10% of eligible patients, per the health organization. The recommendation urges nations and manufacturers to increase availability, via approaches including voluntary licensing. Exclusive production rights on the active ingredient – the primary ingredient of a leading brand – is due to expire in several countries in 2026. The Way Obesity Jabs Work GLP-1 drugs replicate a body's own hormone to delay gastric emptying, curb appetite and enhance the sense of being full so users consume fewer calories. Patients usually start to lose weight in the initial weeks of beginning the once-weekly jabs. Evidence indicates patients may put most of the weight back on after a year of discontinuing the treatment, because their normal appetite come back. Being overweight or obese elevates your risk for experiencing health problems, including type 2 diabetes, heart disease, brain attack, and certain malignancies. Obesity impacts people in all nations and was linked to 3.7 million deaths worldwide in 2024, per the health agency.
Under one in 10 patients that would benefit from weight-loss injections such as Wegovy are able to get them, caution the WHO as it issues its initial recommendations on the medications. Given over a billion individuals worldwide currently classified as obese, it is advocating for more widespread and fairer availability to these injectable treatments. Per projections, over two billion are projected to be living with obesity by 2030 unless action is taken. "Our new guidelines affirms that obesity is a chronic disease that can be addressed with holistic and lifelong support," stated its chief Tedros Adhanom Ghebreyesus. Substantial prices, insufficient output, and distribution challenges are key hurdles to widespread access to the treatments that can aid individuals in losing significant weight, explains the body. GLP-1 Therapy Shortage Despite the present best projected scenario, the manufacturing of GLP-1 therapies would only suffice for around 100 million people – fewer than 10% of eligible patients, per the health organization. The recommendation urges nations and manufacturers to increase availability, via approaches including voluntary licensing. Exclusive production rights on the active ingredient – the primary ingredient of a leading brand – is due to expire in several countries in 2026. The Way Obesity Jabs Work GLP-1 drugs replicate a body's own hormone to delay gastric emptying, curb appetite and enhance the sense of being full so users consume fewer calories. Patients usually start to lose weight in the initial weeks of beginning the once-weekly jabs. Evidence indicates patients may put most of the weight back on after a year of discontinuing the treatment, because their normal appetite come back. Being overweight or obese elevates your risk for experiencing health problems, including type 2 diabetes, heart disease, brain attack, and certain malignancies. Obesity impacts people in all nations and was linked to 3.7 million deaths worldwide in 2024, per the health agency.